Xeris Biopharma Holdings, Inc.
NASDAQ:XERSBiotechnology
+$0.04 today
- Market cap
- $3.10B
- Beta
- 0.90
- P/E (TTM)
- 98.7
- EPS (TTM)
- $0.07
Volume 2.76M
Average 1.66M
XERS Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Xeris Biopharma Holdings, Inc.NASDAQ: XERS
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns positive
Q1 FY2026 net income was $2.23M, compared with -$9.22M a year earlier. Trailing-twelve-month net income was $12.01M.
Context
- Net income amounted to 0.2% of revenue in FY2025, down 26.8 pp from a year earlier.
- Net income increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of $108.5K (-80.4%) for the fiscal year ending Dec 2026, a slowdown from the +101.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $2.23M-79.8% QoQ
- Last fiscal yearDec 2025
- $554K+101.0% YoY
- LTMMar 2026
- $12.01M+126.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +124.2% | +219.6% | +95.4 pp |
| 1 year | +101.0% | -80.4% | -181.4 pp |
| 3-year CAGR | — | +531.8% | — |
| 5-year CAGR | +230.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 554K USD
- Year-over-year change
- +101.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 554K | +101.0% |
| FY2024 | 2024-12-31 | (54.84M) | +11.9% |
| FY2023 | 2023-12-31 | (62.26M) | +34.2% |
| FY2022 | 2022-12-31 | (94.66M) | +22.9% |
| FY2021 | 2021-12-31 | (122.73M) | — |
Net Income vs competitors
How XERS compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +126.6% is the 2nd highest of 9, against a peer median of -1.4%.
- Net income amounts to 3.8% of revenue for XERS, versus a peer median of 15.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | €890.37M EUR | +482.2% | -27.9% | 73.7% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $145.1M USD | +80.3% | +49.3% | — |
| LTM Jun 2026 | $128.76M USD | -3.0% | -1.1% | 15.5% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $59M USD | +0.3% | +20.9% | 61.3% |
| LTM Mar 2026 | $56.41M USD | +34.0% | +29.0% | — | |
| LTM Mar 2026 | $37.19M USD | -32.9% | -5.5% | — | |
| LTM Mar 2026 | $23.91M USD | -179.4% | — | 6.6% | |
| LTM Mar 2026 | $12.01M USD | +126.6% | — | 3.8% | |
| LTM Mar 2026 | $1.48M USD | -67.8% | -20.1% | 1.7% | |
| Peer median (excluding XERS) | — | -1.4% | -1.1% | 15.5% | |
Competitors are the stored peer set for XERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (122.73M) | (94.66M) | (62.26M) | (54.84M) | 554K |
| Depreciation & Amortization | 1.88M | 12.67M | 13.16M | 12.63M | 12.16M |
| Deferred Income Tax | (1.42M) | (1.42M) | (1.25M) | (2.27M) | 0 |
| Stock-Based Compensation | 11.38M | 12.16M | 10.72M | 18.36M | 22.37M |
| Change in Working Capital | 11.85M | (35.15M) | (6.29M) | (8.82M) | (10.36M) |
| Accounts Receivables | (13.37M) | (13.37M) | (8.37M) | (1.22M) | (10.64M) |
| Inventory | (7.47M) | (7.47M) | (14.8M) | (8.78M) | (19.29M) |
| Accounts Payables | (4.32M) | (4.32M) | 6.96M | (9.61M) | (69K) |
| Other Working Capital | 19.98M | (9.99M) | 9.92M | 10.79M | 19.63M |
| Other Non-Cash Items | 3.5M | 3.52M | (1.1M) | (2.05M) | 3.91M |
| Operating Cash Flow | (102.89M) | (102.89M) | (47.02M) | (36.98M) | 28.63M |
| Capital Expenditures | (524K) | (524K) | (2.26M) | (868K) | (696K) |
| Acquisitions (Net) | 38.47M | 0 | 0 | 0 | 0 |
| Purchases of Investments | (43.02M) | 0 | (43.74M) | (34.49M) | 0 |
| Sales of Investments | 34.99M | 34.99M | 40M | 40.24M | 0 |
| Other Investing Activities | 4.55M | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 34.46M | 34.46M | (6M) | 4.88M | (696K) |
| Debt Repayment | 0 | 102.72M | 0 | 38.17M | 9.17M |
| Common Stock Issued | 27M | 30M | 581K | 0 | 13.1M |
| Common Stock Repurchased | (534K) | (468K) | (1.01M) | (3.73M) | (10.88M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (4.78M) | (604K) | 1.73M | 0 |
| Financing Cash Flow | 27.25M | 127.47M | (1.61M) | 36.17M | 11.39M |
| Effect of Forex Changes | (3K) | (4.35M) | 0 | 0 | 0 |
| Net Change in Cash | 59.04M | 59.04M | (54.64M) | 4.07M | 39.32M |
| Free Cash Flow | (103.42M) | (103.42M) | (49.29M) | (37.85M) | 27.93M |
Xeris Biopharma Holdings, Inc.
NASDAQ:XERS
Intrinsic Alpha fair value
Locked
Current Price
$16.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.